Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.

The clinical benefit of anticoagulant treatment for various indications is offset by the risk of bleeding. The impact of bleeding related to vitamin K antagonist (VKA) use, in terms of patients’ discomfort or temporary disability and in terms of both medical and socio-economic resources is not negligible1–4. However, the majority of studies have focused on major bleeding, used obsolete definitions of bleeding and have not distinguished between...